Fracture prevalence and incidence in solid organ transplant recipients

Bart Clarke, Gudrun Leidig-Bruckner

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter summarizes the prevalence of osteoporotic fractures before transplantation, and the incidence of fractures after transplantation in patients undergoing liver, cardiac, lung, and kidney-pancreas transplantation. It also reviews information about the type of fracture, time of fracture occurrence, and risk factors for post-transplantation fracture. Risk factors for the development of bone loss and fracture can be divided into those that influence bone health before transplantation and those that affect bone loss after transplantation. Pre-transplantation risk factors include general risk factors for osteoporosis, such as age, gender, weight or body mass index, underlying endstage disease, comorbidities, and medications known to cause bone loss. The main post-transplantation factors are immunosuppressive medications, duration of immobilization after transplantation, and transplantation-related complications, such as rejection, recovery time, gonadal hormone status, and other factors. Most of the studies reviewed in this chapter reflect clinical experience where standard immunosuppressive regimens typically included glucocorticoids, cyclosporine, tacrolimus, and azathioprine. This makes it easier to draw conclusions about bone loss and fractures in patients undergoing transplantation within the past decade, but harder to assess fracture risk in patients undergoing transplantation today. Relatively few studies are available in patients treated with the newer immunosuppressive agents, such as mycophenolate mofetil or sirolimus.

Original languageEnglish (US)
Title of host publicationBone Disease of Organ Transplantation
PublisherElsevier Inc.
Pages113-158
Number of pages46
ISBN (Print)9780121835026
DOIs
StatePublished - Dec 1 2005

Fingerprint

Transplantation
Transplants
Incidence
Immunosuppressive Agents
Bone Fractures
Bone and Bones
Transplant Recipients
Mycophenolic Acid
Gonadal Hormones
Pancreas Transplantation
Osteoporotic Fractures
Azathioprine
Tacrolimus
Sirolimus
Immobilization
Kidney Transplantation
Cyclosporine
Glucocorticoids
Osteoporosis
Comorbidity

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Clarke, B., & Leidig-Bruckner, G. (2005). Fracture prevalence and incidence in solid organ transplant recipients. In Bone Disease of Organ Transplantation (pp. 113-158). Elsevier Inc.. https://doi.org/10.1016/B978-012183502-6/50008-0

Fracture prevalence and incidence in solid organ transplant recipients. / Clarke, Bart; Leidig-Bruckner, Gudrun.

Bone Disease of Organ Transplantation. Elsevier Inc., 2005. p. 113-158.

Research output: Chapter in Book/Report/Conference proceedingChapter

Clarke, B & Leidig-Bruckner, G 2005, Fracture prevalence and incidence in solid organ transplant recipients. in Bone Disease of Organ Transplantation. Elsevier Inc., pp. 113-158. https://doi.org/10.1016/B978-012183502-6/50008-0
Clarke B, Leidig-Bruckner G. Fracture prevalence and incidence in solid organ transplant recipients. In Bone Disease of Organ Transplantation. Elsevier Inc. 2005. p. 113-158 https://doi.org/10.1016/B978-012183502-6/50008-0
Clarke, Bart ; Leidig-Bruckner, Gudrun. / Fracture prevalence and incidence in solid organ transplant recipients. Bone Disease of Organ Transplantation. Elsevier Inc., 2005. pp. 113-158
@inbook{7953b00181724294b36dee5f7f15cdc5,
title = "Fracture prevalence and incidence in solid organ transplant recipients",
abstract = "This chapter summarizes the prevalence of osteoporotic fractures before transplantation, and the incidence of fractures after transplantation in patients undergoing liver, cardiac, lung, and kidney-pancreas transplantation. It also reviews information about the type of fracture, time of fracture occurrence, and risk factors for post-transplantation fracture. Risk factors for the development of bone loss and fracture can be divided into those that influence bone health before transplantation and those that affect bone loss after transplantation. Pre-transplantation risk factors include general risk factors for osteoporosis, such as age, gender, weight or body mass index, underlying endstage disease, comorbidities, and medications known to cause bone loss. The main post-transplantation factors are immunosuppressive medications, duration of immobilization after transplantation, and transplantation-related complications, such as rejection, recovery time, gonadal hormone status, and other factors. Most of the studies reviewed in this chapter reflect clinical experience where standard immunosuppressive regimens typically included glucocorticoids, cyclosporine, tacrolimus, and azathioprine. This makes it easier to draw conclusions about bone loss and fractures in patients undergoing transplantation within the past decade, but harder to assess fracture risk in patients undergoing transplantation today. Relatively few studies are available in patients treated with the newer immunosuppressive agents, such as mycophenolate mofetil or sirolimus.",
author = "Bart Clarke and Gudrun Leidig-Bruckner",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/B978-012183502-6/50008-0",
language = "English (US)",
isbn = "9780121835026",
pages = "113--158",
booktitle = "Bone Disease of Organ Transplantation",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Fracture prevalence and incidence in solid organ transplant recipients

AU - Clarke, Bart

AU - Leidig-Bruckner, Gudrun

PY - 2005/12/1

Y1 - 2005/12/1

N2 - This chapter summarizes the prevalence of osteoporotic fractures before transplantation, and the incidence of fractures after transplantation in patients undergoing liver, cardiac, lung, and kidney-pancreas transplantation. It also reviews information about the type of fracture, time of fracture occurrence, and risk factors for post-transplantation fracture. Risk factors for the development of bone loss and fracture can be divided into those that influence bone health before transplantation and those that affect bone loss after transplantation. Pre-transplantation risk factors include general risk factors for osteoporosis, such as age, gender, weight or body mass index, underlying endstage disease, comorbidities, and medications known to cause bone loss. The main post-transplantation factors are immunosuppressive medications, duration of immobilization after transplantation, and transplantation-related complications, such as rejection, recovery time, gonadal hormone status, and other factors. Most of the studies reviewed in this chapter reflect clinical experience where standard immunosuppressive regimens typically included glucocorticoids, cyclosporine, tacrolimus, and azathioprine. This makes it easier to draw conclusions about bone loss and fractures in patients undergoing transplantation within the past decade, but harder to assess fracture risk in patients undergoing transplantation today. Relatively few studies are available in patients treated with the newer immunosuppressive agents, such as mycophenolate mofetil or sirolimus.

AB - This chapter summarizes the prevalence of osteoporotic fractures before transplantation, and the incidence of fractures after transplantation in patients undergoing liver, cardiac, lung, and kidney-pancreas transplantation. It also reviews information about the type of fracture, time of fracture occurrence, and risk factors for post-transplantation fracture. Risk factors for the development of bone loss and fracture can be divided into those that influence bone health before transplantation and those that affect bone loss after transplantation. Pre-transplantation risk factors include general risk factors for osteoporosis, such as age, gender, weight or body mass index, underlying endstage disease, comorbidities, and medications known to cause bone loss. The main post-transplantation factors are immunosuppressive medications, duration of immobilization after transplantation, and transplantation-related complications, such as rejection, recovery time, gonadal hormone status, and other factors. Most of the studies reviewed in this chapter reflect clinical experience where standard immunosuppressive regimens typically included glucocorticoids, cyclosporine, tacrolimus, and azathioprine. This makes it easier to draw conclusions about bone loss and fractures in patients undergoing transplantation within the past decade, but harder to assess fracture risk in patients undergoing transplantation today. Relatively few studies are available in patients treated with the newer immunosuppressive agents, such as mycophenolate mofetil or sirolimus.

UR - http://www.scopus.com/inward/record.url?scp=84882412954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882412954&partnerID=8YFLogxK

U2 - 10.1016/B978-012183502-6/50008-0

DO - 10.1016/B978-012183502-6/50008-0

M3 - Chapter

AN - SCOPUS:84882412954

SN - 9780121835026

SP - 113

EP - 158

BT - Bone Disease of Organ Transplantation

PB - Elsevier Inc.

ER -